|  | ECLS (N=288) | ECMELLA (N=129) | Overall (N=417) |
| --- | --- | --- | --- |
| **Age (years)** |  |  |  |
| Mean (SD) | 62.9 (13.7) | 59.3 (12.9) | 61.8 (13.6) |
| Median [Min, Max] | 65.0 [18.0, 87.0] | 61.0 [21.0, 83.0] | 63.5 [18.0, 87.0] |
| Missing | 0 (0%) | 1 (0.8%) | 1 (0.2%) |
| **Sex** |  |  |  |
| female | 84 (29.2%) | 29 (22.5%) | 113 (27.1%) |
| male | 204 (70.8%) | 100 (77.5%) | 304 (72.9%) |
| **BMI** |  |  |  |
| Mean (SD) | 28.0 (5.91) | 27.5 (5.92) | 27.9 (5.91) |
| Median [Min, Max] | 27.4 [15.8, 49.6] | 26.3 [17.8, 51.5] | 26.8 [15.8, 51.5] |
| Missing | 33 (11.5%) | 4 (3.1%) | 37 (8.9%) |
| **Diabetes (Type II)** |  |  |  |
| Yes | 83 (28.8%) | 55 (42.6%) | 138 (33.1%) |
| No | 192 (66.7%) | 70 (54.3%) | 262 (62.8%) |
| Missing | 13 (4.5%) | 4 (3.1%) | 17 (4.1%) |
| **Chronic kidney disease** |  |  |  |
| Yes | 72 (25.0%) | 35 (27.1%) | 107 (25.7%) |
| No | 202 (70.1%) | 86 (66.7%) | 288 (69.1%) |
| Missing | 14 (4.9%) | 8 (6.2%) | 22 (5.3%) |
| **Chronic obstructive pulmonary disease** |  |  |  |
| Yes | 34 (11.8%) | 16 (12.4%) | 50 (12.0%) |
| No | 242 (84.0%) | 102 (79.1%) | 344 (82.5%) |
| Missing | 12 (4.2%) | 11 (8.5%) | 23 (5.5%) |
| **Lactate (mg/dL)** |  |  |  |
| Mean (SD) | 73.2 (53.7) | 70.7 (45.6) | 72.5 (51.4) |
| Median [Min, Max] | 61.0 [4.00, 229] | 60.0 [4.00, 200] | 61.0 [4.00, 229] |
| Missing | 43 (14.9%) | 25 (19.4%) | 68 (16.3%) |
| **Median pH** |  |  |  |
| Mean (SD) | 744 (6.37) | 743 (7.46) | 743 (6.79) |
| Median [Min, Max] | 744 [717, 764] | 744 [704, 756] | 744 [704, 764] |
| Missing | 64 (22.2%) | 5 (3.9%) | 69 (16.5%) |
| **Vasoactive-inotropic score (VIS)ᵇ** |  |  |  |
| Mean (SD) | 491000000000000 (4060000000000000) | 654000000000000 (3650000000000000) | 541000000000000 (3940000000000000) |
| Median [Min, Max] | 127 [1.00, 42900000000000000] | 76.0 [4.00, 29600000000000000] | 102 [1.00, 42900000000000000] |
| Missing | 30 (10.4%) | 17 (13.2%) | 47 (11.3%) |
| **RRT required (prior to tMCS)** |  |  |  |
| Yes | 36 (12.5%) | 13 (10.1%) | 49 (11.8%) |
| No | 249 (86.5%) | 114 (88.4%) | 363 (87.1%) |
| Missing | 3 (1.0%) | 2 (1.6%) | 5 (1.2%) |
| **pre\_crea** |  |  |  |
| Yes | 0 (0%) | 0 (0%) | 0 (0%) |
| No | 0 (0%) | 0 (0%) | 0 (0%) |
| Missing | 288 (100%) | 129 (100%) | 417 (100%) |
| **Etiology of cardiogenic shock** |  |  |  |
| AHF | 48 (16.7%) | 53 (41.1%) | 101 (24.2%) |
| AMICS | 48 (16.7%) | 40 (31.0%) | 88 (21.1%) |
| Other | 60 (20.8%) | 11 (8.5%) | 71 (17.0%) |
| PCCS | 131 (45.5%) | 25 (19.4%) | 156 (37.4%) |
| Missing | 1 (0.3%) | 0 (0%) | 1 (0.2%) |
| **Previous cardiac arrest** |  |  |  |
| Yes | 98 (34.0%) | 54 (41.9%) | 152 (36.5%) |
| No | 190 (66.0%) | 75 (58.1%) | 265 (63.5%) |
| **eCPR** |  |  |  |
| Yes | 16 (5.6%) | 6 (4.7%) | 22 (5.3%) |
| No | 272 (94.4%) | 123 (95.3%) | 395 (94.7%) |
| **Nephrotoxic drugsᶜ** |  |  |  |
| Yes | 76 (26.4%) | 58 (45.0%) | 134 (32.1%) |
| No | 212 (73.6%) | 71 (55.0%) | 283 (67.9%) |
| ᵃ Stage 3a and 3b were coded as 3 and 4, respectively. The remaining stages were increased by one value.<br>ᵇ VIS, a weighted sum of vasopressor and inotropic medications, quantifies the amount of pharmacological cardiovascular support in patients on tMCS.<br>ᶜ Vancomycin (IV), gentamycin, or tobramycin | | | |